Synagis (Palivizumab) Patient Information: Missed a Dose and What Should I Avoid at RxList

Pill Identifier Search

May 27, 2012

Synagis

Respiratory Syncytial Virus »

Respiratory syncytial virus (RSV) facts

RSV is a highly contagious virus infection that most commonly causes illness during the winter season.
Most children who develop an RSV infection have mild symptoms of fever, nasal congestion, and nasal discharge.
High-risk groups are more likely to have a more severe disease process, including wheezing (bronchiolitis in infants) and/or pneumonia. Such high-risk groups include premature infants, those children with a compromised immune system, or those with chronic pulmonary disease or congenital/acquired cardiac disease.
Supportive care is the mainstay of therapy. For high-risk patients, palivizumab (Synagis) preventative therapy is available.

What is the respiratory syncytial virus (RSV)?

The respiratory syncytial virus (RSV), discovered in 1956, is capable of causing a broad spectrum of illnesses. Older children and adults will commonly e...

Read the Respiratory Syncytial Virus article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Synagis User Reviews >>

Synagis

Adult Skin Problems Slideshow Pictures

How Smoking Affects Your Looks Slideshow Pictures

Weight Gain Shockers Slideshow

font size

Synagis Patient Information including If I Miss a Dose

What happens if I miss a dose (Synagis)?

Call your doctor for instructions if you miss an appointment for your child's palivizumab injection.

What happens if I overdose (Synagis)?

Seek emergency medical attention if you think your child has received too much of this medicine.

Symptoms of a palivizumab overdose are not known.

What should I avoid while receiving palivizumab (Synagis)?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What other drugs will affect palivizumab (Synagis)?

There may be other drugs that can interact with palivizumab. Tell your doctor about all the prescription and over-the-counter medications your child has received. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your child's doctor.

Where can I get more information?

Your doctor or pharmacist can provide more information about palivizumab.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2010 Cerner Multum, Inc. Version: 2.01. Revision date: 06/29/2009.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.